Impact on survival of severe immuno-related adverse events in deficient mismatch repair/microsatellite instable-high digestive cancers treated with immunotherapy
Journal for ImmunoTherapy of Cancer · 2026-07 · 14 (7) · e015273
DOI: 10.1136/jitc-2026-015273 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 24.07.2026. Verfasst von David Tougeron und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Poitiers University Hospital, Poitiers, France david.tougeron@chu-poitiers.fr. Hauptthemen laut MEDLINE: Digestive System Neoplasms, DNA Mismatch Repair, Immune Checkpoint Inhibitors, Immunotherapy. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Deficient DNA mismatch repair/microsatellite instability-high (dMMR/MSI-H) cancers are very sensitive to immune checkpoint inhibitors (ICIs), yet their use is frequently complicated by immune-related adverse events (irAEs). Our study analyzed the impact of grade ≥3 irAEs (immune-related severe adverse events (irSAEs)) on survival in patients with dMMR/MSI-H digestive cancers treated with ICIs.
Methods
We conducted an international, multicenter, ambispective study involving 1,175 patients from 34 centers. The primary endpoint was the correlation between the occurrence of irSAEs and progression-free survival (PFS). Secondary endpoints included factors associated with irSAEs, correlation between irSAEs and overall response rate (ORR) and overall survival (OS). Prespecified landmark and time-dependent survival models were used to account for the time to irSAE occurrence.
Results
Among 1,175 patients treated with ICIs for digestive cancers, 49.1% were female, median age was 66.9 years (IQR 53.7–77.3) and 82.9% had colorectal cancer. Overall, 382 patients (32.5%) had an irAE, including 117 (10.0%) irSAEs. Median time to irSAEs occurrence was 3.78 months (IQR 1.97–7.62). The most frequent irSAEs were gastrointestinal (3.4%), hepatic (1.8%) and dermatologic (1.0%). The only factor associated with irSAEs was the use of an ICI combination versus monotherapy (20.0% vs 11.4%, p=0.03). Among patients with irSAEs, 71.5% received oral and 29.8% intravenous corticosteroids, and 15.7% immunosuppressive agents. Overall, in 26.9% of patients, ICIs were resumed following irSAEs, with an irAE recurrence rate of 57.1%. irSAE was associated with a better ORR (48.6% vs 34.6%, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Poitiers University Hospital, Poitiers, France david.tougeron@chu-poitiers.fr.
- Department of Gastroenterology and Hepatology, Poitiers University Hospital, Poitiers, France.
- Department of Medical Oncology, Foundation IRCCS National Cancer Institute, Milan, Italy.
- Department of Methodology, Federation Francophone de Cancerologie Digestive, Dijon, France.
- Oncologia Medica, Istituto Oncologico Veneto Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy.
- Department of Oncology, Mayo Clinc, Rochester, Minnesota, USA.
Zitieren
APA
Tougeron, D., Kauffmann, C., Ambrosini, M., Boussari, O., Lonardi, S., Sinicrope, F. A., Fakih, M., Overman, M. J., Elez, E., Turpin, A., Decraecker, M., Hollebecque, A., Pernot, S., Mazard, T., Dutherage, M., Cohen, R., Sclafani, F., Ben Abdelghani, M., Aparicio, T., …, & Alouani, E. (2026). Impact on survival of severe immuno-related adverse events in deficient mismatch repair/microsatellite instable-high digestive cancers treated with immunotherapy. Journal for ImmunoTherapy of Cancer, 14(7), e015273. https://doi.org/10.1136/jitc-2026-015273
Vancouver
Tougeron D, Kauffmann C, Ambrosini M, Boussari O, Lonardi S, Sinicrope FA, et al. Impact on survival of severe immuno-related adverse events in deficient mismatch repair/microsatellite instable-high digestive cancers treated with immunotherapy. Journal for ImmunoTherapy of Cancer. 2026;14(7):e015273. doi:10.1136/jitc-2026-015273
BibTeX
@article{Tougeron2026,
author = {Tougeron, David and Kauffmann, Charles and Ambrosini, Margherita and Boussari, Olayide and Lonardi, Sara and Sinicrope, Frank A and Fakih, Marwan and Overman, Michael J and Elez, Elena and Turpin, Anthony and Decraecker, Marie and Hollebecque, Antoine and Pernot, Simon and Mazard, Thibault and Dutherage, Marie and Cohen, Romain and Sclafani, Francesco and Ben Abdelghani, Mohamed and Aparicio, Thomas and Coutzac, Clélia and Hautefeuille, Vincent and Muller, Marie and Cremolini, Chiara and Guimbaud, Rosine and Taieb, Julien and Pietrantonio, Filippo and Olivier, Raphael and Alouani, Emily},
title = {Impact on survival of severe immuno-related adverse events in deficient mismatch repair/microsatellite instable-high digestive cancers treated with immunotherapy},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {7},
pages = {e015273},
doi = {10.1136/jitc-2026-015273}
}
EUVIMED